Benitec Biopharma Ltd ADR Cash Flow Conversion Efficiency
Benitec Biopharma Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Benitec Biopharma Ltd ADR (BNTC) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.78 Million) by net assets ($187.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Benitec Biopharma Ltd ADR (2013–2025)
Cash flow conversion efficiency of Benitec Biopharma Ltd ADR from 2013 to 2025. This chart illustrates how Benitec Biopharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Benitec Biopharma Ltd ADR stock price today for real-time trading data and today's change.
Benitec Biopharma Ltd ADR Cash Flow Conversion Ratio Explained
Benitec Biopharma Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Benitec Biopharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Benitec Biopharma Ltd ADR ranked by their cash flow conversion efficiency. Also see Benitec Biopharma Ltd ADR market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Jinyi Media Corp
SHE:002905
|
2.017x |
|
Actron Technology
TWO:8255
|
0.039x |
|
Objective Corporation Ltd
AU:OCL
|
0.194x |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
0.015x |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
0.015x |
|
CN EVERBRIGHT WATER HD 1
F:BIU2
|
N/A |
|
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd B
SHG:900932
|
-0.096x |
|
YASHO INDUSTRIES ORD (BSE)
NSE:YASHO
|
0.139x |
Annual Cash Flow Conversion Efficiency for Benitec Biopharma Ltd ADR (2013–2025)
The table below shows the annual cash flow conversion efficiency of Benitec Biopharma Ltd ADR from 2013 to 2025. Review Benitec Biopharma Ltd ADR free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $97.30 Million | $-23.59 Million | -0.242x | +40.96% |
| 2024-06-30 | $47.25 Million | $-19.40 Million | -0.411x | +99.54% |
| 2023-06-30 | $202.00K | $-18.01 Million | -89.168x | -1516.35% |
| 2022-06-30 | $2.88 Million | $-15.90 Million | -5.517x | -760.26% |
| 2021-06-30 | $20.01 Million | $-12.83 Million | -0.641x | +12.87% |
| 2020-06-30 | $10.24 Million | $-7.54 Million | -0.736x | -354.60% |
| 2019-06-30 | $16.57 Million | $4.79 Million | 0.289x | +146.55% |
| 2018-06-30 | $13.77 Million | $-8.55 Million | -0.621x | -23.59% |
| 2017-06-30 | $16.53 Million | $-8.30 Million | -0.502x | +65.02% |
| 2016-06-30 | $14.07 Million | $-20.21 Million | -1.437x | -171.46% |
| 2015-06-30 | $18.31 Million | $-9.69 Million | -0.529x | -22.75% |
| 2014-06-30 | $22.48 Million | $-9.69 Million | -0.431x | -42.34% |
| 2013-06-30 | $30.61 Million | $-9.27 Million | -0.303x | -- |
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more